Hagen Ott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hagen Ott has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Lars Lange
GFO Kliniken Bonn
4 shared publications - Matthias Volkmar Kopp
Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
4 shared publications H.F. Merk
Department of Dermatology and Allergology University Hospital of the RWTH Aachen Germany
2 shared publications- Agnes Schwieger-Briel
Department of Dermatology, Medical Center - University of Freiburg, Germany
1 shared publication - Albrecht Bufe
Experimental Pneumology, Ruhr University, Bochum, Germany
1 shared publication - Birgit Mattulat
Children’s Hospital “Klinik am Eichert”, Goeppingen, Germany
1 shared publication
Latest Publications
- Open Access
- 10 December 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-12
Bullous pemphigoid in infants: characteristics, diagnosis and treatment
Bullous pemphigoid (BP) in infants is a rare but increasingly reported autoimmune blistering skin disease. Autoantibody reactivity is usually poorly characterized. Current guidelines do not address specific aspects of the infantile form of BP. The objectives of this study are to define clinical and diagnostic characteristics of infantile BP and develop a treatment algorithm. Detailed characterization of a current case series of five infants with BP from our departments. Comprehensive analysis of all reported cases (1–12 months) with respect to clinical and laboratory characteristics, treatment and outcome. In total 81 cases were identified (including our own). The mean age was 4.5 months. Moderately severe and severe disease was seen in 84% of cases. Involvement of hands and feet was present in all cases. Immunofluorescence microscopy was comparable with BP in adults. Where analyzed, the NC16A domain of bullous pemphigoid 180 kDa antigen/collagen XVII (BP180) was identified as the major target antigen. BP180 NC16A ELISA values in our cohort were significantly higher than in a control cohort of 28 newly diagnosed adult patients. 50% of patients were treated with systemic corticosteroids, 20% with a combination of systemic corticosteroids and dapsone or sulfapyridine and 10% with topical corticosteroids alone. 14% of patients needed a combination of multiple immunosuppressants. All but one patient reached remission. Relapses were rare. Presentation of infantile BP is often severe with blistering of hands and feet present in all cases. Pathogenesis and diagnostic criteria are comparable to adult BP, yet BP180 NC16A ELISA levels seem to be significantly higher in infants. The overall disease outcome is favorable. Based on the results of this study we propose a treatment algorithm for infantile BP.
- 10 December 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-12
Open AccessBullous pemphigoid in infants: characteristics, diagnosis and treatment
Bullous pemphigoid (BP) in infants is a rare but increasingly reported autoimmune blistering skin disease. Autoantibody reactivity is usually poorly characterized. Current guidelines do not address specific aspects of the infantile form of BP. The objectives of this study are to define clinical and diagnostic characteristics of infantile BP and develop a treatment algorithm. Detailed characterization of a current case series of five infants with BP from our departments. Comprehensive analysis of all reported cases (1–12 months) with respect to clinical and laboratory characteristics, treatment and outcome. In total 81 cases were identified (including our own). The mean age was 4.5 months. Moderately severe and severe disease was seen in 84% of cases. Involvement of hands and feet was present in all cases. Immunofluorescence microscopy was comparable with BP in adults. Where analyzed, the NC16A domain of bullous pemphigoid 180 kDa antigen/collagen XVII (BP180) was identified as the major target antigen. BP180 NC16A ELISA values in our cohort were significantly higher than in a control cohort of 28 newly diagnosed adult patients. 50% of patients were treated with systemic corticosteroids, 20% with a combination of systemic corticosteroids and dapsone or sulfapyridine and 10% with topical corticosteroids alone. 14% of patients needed a combination of multiple immunosuppressants. All but one patient reached remission. Relapses were rare. Presentation of infantile BP is often severe with blistering of hands and feet present in all cases. Pathogenesis and diagnostic criteria are comparable to adult BP, yet BP180 NC16A ELISA levels seem to be significantly higher in infants. The overall disease outcome is favorable. Based on the results of this study we propose a treatment algorithm for infantile BP.
- 28 March 2014
- Published by Springer Nature
- p. 103-130
Therapieprinzipien
- 28 March 2014
- Published by Springer Nature
- p. 63-101
Allergologische Diagnostik
- 28 March 2014
- Published by Springer Nature
- p. 39-62
Allergenkunde kompakt
- 28 March 2014
- Published by Springer Nature
- p. 15-38
Genetik, Epidemiologie und Prävention
- 28 March 2014
- Published by Springer Nature
- p. 315-333
Dosierungstabellen
- 28 March 2014
- Published by Springer Nature
- p. 269-285
Arzneimittelallergie und -intoleranz
- 28 March 2014
- Published by Springer Nature
- p. 211-225
Urtikaria
- 28 March 2014
- Published by Springer Nature
- p. 199-209
Allergisches Kontaktekzem
- 10 January 2013
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (1) , 100-107
Molecular microarray analysis reveals allergen‐ and exotoxin‐specific IgE repertoires in children with atopic dermatitis
Background: Children suffering from atopic dermatitis frequently show allergen‐specific sensitization. However, the corresponding IgE‐recognition patterns have not yet been extensively characterized using multiallergen microarrays.Objective: To provide comprehensive, molecular IgE repertoires in paediatric patients with atopic dermatitis using microarray technology.Methods: Sera of 140 affected children were screened with a protein microarray containing a panel of 95 inhalant, food and staphylococcal antigen components. In addition, total serum IgE levels and further clinical parameters were recorded.Results: At a mean total IgE level of 1528 kU/L, the number of sensitizations varied from 0 to 32 per patient, and regression analysis revealed a significant association between total IgE and the quantity of recognized antigens. A total of 78 single allergen and microbial components elicited at least one IgE response, while 11 plant and 13 non‐plant molecules were recognized by more than 10% of patients. Specific IgE against Staphylococcus aureus could be detected in 14% of children. Sensitization rates against the studied allergen molecules differed significantly when stratified by age. Whereas reactivity against inhalant allergens and SEC was lowest in the youngest group (<24 months) reaching highest values in children ≥72 months, IgE responses against food allergen components peaked in younger age groups (0–48 months) and clearly declined in patients of higher age. The large amount of microarray data could be aggregated by centroid cluster analysis revealing valid allergen clusters possibly linked with higher disease severity as determined by multivariate analysis of covariance.Conclusion: Allergenic molecule microarray analysis can be regarded as a suitable research tool for large‐scale IgE screening in infants and children with atopic dermatitis (AD). Still, further studies in well‐defined populations are needed to exactly identify its tangible benefits in the diagnostic and therapeutic management of affected patients in daily clinical practice.
- 10 January 2013
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (1) , 100-107
Molecular microarray analysis reveals allergen‐ and exotoxin‐specific IgE repertoires in children with atopic dermatitis
Background: Children suffering from atopic dermatitis frequently show allergen‐specific sensitization. However, the corresponding IgE‐recognition patterns have not yet been extensively characterized using multiallergen microarrays.Objective: To provide comprehensive, molecular IgE repertoires in paediatric patients with atopic dermatitis using microarray technology.Methods: Sera of 140 affected children were screened with a protein microarray containing a panel of 95 inhalant, food and staphylococcal antigen components. In addition, total serum IgE levels and further clinical parameters were recorded.Results: At a mean total IgE level of 1528 kU/L, the number of sensitizations varied from 0 to 32 per patient, and regression analysis revealed a significant association between total IgE and the quantity of recognized antigens. A total of 78 single allergen and microbial components elicited at least one IgE response, while 11 plant and 13 non‐plant molecules were recognized by more than 10% of patients. Specific IgE against Staphylococcus aureus could be detected in 14% of children. Sensitization rates against the studied allergen molecules differed significantly when stratified by age. Whereas reactivity against inhalant allergens and SEC was lowest in the youngest group (<24 months) reaching highest values in children ≥72 months, IgE responses against food allergen components peaked in younger age groups (0–48 months) and clearly declined in patients of higher age. The large amount of microarray data could be aggregated by centroid cluster analysis revealing valid allergen clusters possibly linked with higher disease severity as determined by multivariate analysis of covariance.Conclusion: Allergenic molecule microarray analysis can be regarded as a suitable research tool for large‐scale IgE screening in infants and children with atopic dermatitis (AD). Still, further studies in well‐defined populations are needed to exactly identify its tangible benefits in the diagnostic and therapeutic management of affected patients in daily clinical practice.